China set to overtake USA bioscience market

26 February 2014

Bioscience research in China is set to overtake the USA within the next five to ten years, data from antibody search engine CiteAb suggests.

CiteAb, spun out from the University of Bath, UK, in early February 2014, has a database containing over 1.8 million antibodies from suppliers all over the world, and uses academic research citations to rank antibodies. This gives the company an overview of the amount of research being carried out in over 100 different countries.

Andrew Chalmers, founder of CiteAb, said: “Our data highlights the number of academic research papers using antibodies that are produced by each country, and therefore acts as a fantastic indicator of bioscience research activity around the world. The data we’ve pulled from CiteAb clearly shows that China is the big winner at the moment. The United States has been the most productive nation in bioscience research for a long time, but has seen a gradual decrease in output since 2010. Conversely, China’s output has been growing enormously since around 2009 and if current trends continue we expect to see China overtake the USA by as soon as 2020. To counter this, the USA will need to increase investment in bioscience research.”

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight





More Features in Biotechnology